Form D · Biotechnology
Modifi Biosciences, Inc.
New Haven, CT · CIK 0001922279
Offering snapshot reported Aug 29, 2024 · SEC filing
- Reported sold
- $996K Offering amount: $1M
- Investors reported
- 39 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 19, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 29, 2024 | Initial | $995,503 | No comparison | 39 | SEC filing |
| Aug 3, 2023 | Amendment | $10,474,023 | $4,799,987vs Apr 19, 2022 | 40 | SEC filing |
| Apr 19, 2022 | Initial | $5,674,036 | No comparison | 32 | SEC filing |
Offering details
- Securities
- Debt, Option to acquire, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-522797
Convertible Promissory Notes
Source: Form D, filed Aug 29, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Ranjit Bindra | Director |
| Lucas De Breed | Director |
| Seth Herzon | Director |
| Kat Kayser Bricker | Director |
| Kevin L. Rakin | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
55 Church Street
New Haven, CT, 06510
New Haven, CT, 06510